Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-067513
Filing Date
2025-05-09
Accepted
2025-05-09 08:00:20
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pmvp-20250331.htm   iXBRL 10-Q 1667194
2 EX-10.1 pmvp-ex10_1.htm EX-10.1 29382
3 EX-10.2 pmvp-ex10_2.htm EX-10.2 34576
4 EX-10.3 pmvp-ex10_3.htm EX-10.3 23191
5 EX-31.1 pmvp-ex31_1.htm EX-31.1 17890
6 EX-31.2 pmvp-ex31_2.htm EX-31.2 17865
7 EX-32.1 pmvp-ex32_1.htm EX-32.1 9788
8 EX-32.2 pmvp-ex32_2.htm EX-32.2 10077
9 GRAPHIC img151252686_0.jpg GRAPHIC 51489
  Complete submission text file 0000950170-25-067513.txt   7744889

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pmvp-20250331.xsd EX-101.SCH 1013060
76 EXTRACTED XBRL INSTANCE DOCUMENT pmvp-20250331_htm.xml XML 1388416
Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Filer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39539 | Film No.: 25928434
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)